The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As clinical-stage pharmaceutical companies increasingly need cash to fund drug development, Helus Pharma closed a US$50 million underwritten offering. The offering consisted of 10,309,280 common shares at US$4.85 per share, according to a company press release.
The deal represents significant dilution for existing shareholders, adding over 10 million new shares to a company that remains pre-revenue and loss-making. Helus has not specified the use of proceeds, but the capital is expected to support ongoing research and development expenses.
Sign in to access this content
Sign InHELP shares closed at $4.85 on June 23, 2026, exactly at the offering price, after trading between $4.75 and $5.05 during the session. No near-term catalysts appear on the calendar, leaving the focus on the company's ability to deliver clinical milestones that can justify its valuation.